BillionToOne 10-Q: Q3 Revenue $123.0M, Profit $17.4M, Material Weaknesses Persist
BLLN sits 82% above its 52-week low of $61.96.
Summary
BillionToOne's Q3 10-Q confirms $123.0 million of revenue (up 47%), $17.4 million of net income and $561.5 million of cash, while disclosing that its material weaknesses in internal controls remain unremediated and that Illumina's patent suit over the UNITY test is pending.
Key Events · Earnings and Guidance · BLLN
-
Q3 Revenue Up 47% to $123.0M
Revenue rose to $122.98 million from $83.52 million a year earlier, with oncology testing at $17.05 million versus $8.69 million and prenatal at $104.29 million versus $74.07 million.
-
Net Income $17.4M, 71% Gross Margin
Gross profit was $87.1 million on a 71% margin, income from operations $11.0 million, and net income $17.39 million, or $0.32 per diluted share.
-
Material Weaknesses Still Unremediated
Management concluded disclosure controls were not effective at September 30, 2026 because previously reported material weaknesses — control environment, financial-instrument accounting and user access — remained unremediated.
-
Illumina Patent Suit Pending
Illumina sued on May 7, 2026 alleging the UNITY test infringes three U.S. patents; BillionToOne filed a motion to dismiss on October 23, 2026 and does not believe a loss is probable or estimable.
Analysis · BLLN · Industrial Applications And Services
The headline numbers were already out on November 4 — revenue of $123.0 million, up 47%, and 2026 guidance raised to $460-470 million — so the income statement itself is not new. What the 10-Q adds is the balance sheet and the risk disclosures: $561.5 million of cash, $89.0 million of Oberland debt after the $30.0 million third tranche, and, most importantly, disclosure controls still concluded not effective because the previously reported material weaknesses in internal control over financial reporting remained unremediated as of September 30, 2026. It also puts the Illumina patent suit on the record: filed May 7, 2026 over the UNITY test, with a motion to dismiss filed October 23, 2026 and no loss accrued. A fast-growing, newly profitable diagnostics company with a clean balance sheet is the story; the unresolved controls problem and the patent fight are the caveats that keep it from being a clean beat.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLLN was trading at $113.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $61.96 to $150.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.